These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15747247)

  • 1. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.
    Greenberg DP; Walker RE; Lee MS; Reisinger KS; Ward JI; Yogev R; Blatter MM; Yeh SH; Karron RA; Sangli C; Eubank L; Coelingh KL; Cordova JM; August MJ; Mehta HB; Chen W; Mendelman PM
    J Infect Dis; 2005 Apr; 191(7):1116-22. PubMed ID: 15747247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
    Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
    J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
    Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
    J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of vaccines for parainfluenza virus infections.
    Sato M; Wright PF
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S123-5. PubMed ID: 18820572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
    Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
    Englund JA; Karron RA; Cunningham CK; Larussa P; Melvin A; Yogev R; Handelsman E; Siberry GK; Thumar B; Schappell E; Bull CV; Chu HY; Schaap-Nutt A; Buchholz U; Collins PL; Schmidt AC;
    Vaccine; 2013 Nov; 31(48):5706-12. PubMed ID: 24103895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
    Belshe RB; Newman FK; Tsai TF; Karron RA; Reisinger K; Roberton D; Marshall H; Schwartz R; King J; Henderson FW; Rodriguez W; Severs JM; Wright PF; Keyserling H; Weinberg GA; Bromberg K; Loh R; Sly P; McIntyre P; Ziegler JB; Hackell J; Deatly A; Georgiu A; Paschalis M; Wu SL; Tatem JM; Murphy B; Anderson E
    J Infect Dis; 2004 Feb; 189(3):462-70. PubMed ID: 14745704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
    Gomez M; Mufson MA; Dubovsky F; Knightly C; Zeng W; Losonsky G
    Pediatr Infect Dis J; 2009 Jul; 28(7):655-8. PubMed ID: 19483659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
    Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
    Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.
    Slobod KS; Shenep JL; Luján-Zilbermann J; Allison K; Brown B; Scroggs RA; Portner A; Coleclough C; Hurwitz JL
    Vaccine; 2004 Aug; 22(23-24):3182-6. PubMed ID: 15297072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants.
    Lee MS; Mendelman PM; Sangli C; Cho I; Mathie SL; August MJ
    J Infect Dis; 2001 Apr; 183(8):1281-4. PubMed ID: 11262213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants.
    Bernstein DI; Falloon J; Yi T
    Vaccine; 2011 Sep; 29(40):7042-8. PubMed ID: 21782874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.
    Karron RA; Thumar B; Schappell E; Surman S; Murphy BR; Collins PL; Schmidt AC
    Vaccine; 2012 Jun; 30(26):3975-81. PubMed ID: 22178099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.
    Karron RA; Casey R; Thumar B; Surman S; Murphy BR; Collins PL; Schmidt AC
    Pediatr Infect Dis J; 2011 Oct; 30(10):e186-91. PubMed ID: 21829138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.
    Madhi SA; Cutland C; Zhu Y; Hackell JG; Newman F; Blackburn N; Murphy BR; Belshe RB; Karron RA; Deatly AM; Gruber WC; Bernstein DI; Wright PF
    Vaccine; 2006 Mar; 24(13):2432-9. PubMed ID: 16406170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge.
    Greer CE; Zhou F; Legg HS; Tang Z; Perri S; Sloan BA; Megede JZ; Uematsu Y; Vajdy M; Polo JM
    Vaccine; 2007 Jan; 25(3):481-9. PubMed ID: 17052811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIV-3 vaccine National Institutes of Health/Aviron.
    Jones T
    Curr Opin Investig Drugs; 2001 Jul; 2(7):890-2. PubMed ID: 11757785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.
    Haller AA; Mitiku M; MacPhail M
    J Gen Virol; 2003 Aug; 84(Pt 8):2153-2162. PubMed ID: 12867647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
    Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
    J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.